Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$4.6MCash on Hand
8.3mo Cash Runway
Follow DYAI by emailGet an email when DYAI reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about DYAI, unsubscribe in one click. Privacy
📣 What DYAI Says Is Next
first quarter of 2027 · “Results are anticipated in the first quarter of 2027.”
Company press release, Nov 13, 2026 · SEC filing
in 2026 · “Non-Animal Dairy Enzymes: Dyadic’s partner Inzymes announced plans to launch recombinant non-animal bovine chymosin in 2026 following achievement of development milestones.”
Company press release, Mar 25, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 13, 2026 ·
Earnings Dyadic reported Q3 2026 results and recorded its first direct commercial protein sales, mainly transferrin and DNase I, though amounts were not material. Inzymes' camel chymosin first sale triggers a $225,000 milestone expected in Q4 2026. Form 8-K · SEC filing · Press release
Sep 25, 2026 ·
Listing Received two Nasdaq deficiency notices: the bid price has been below $1 for 30 consecutive business days, and market value of listed securities has been below $35 million for the same period. Compliance deadline is March 24, 2027, and the company may appeal any delisting determination. Form 8-K · SEC filing
Sep 18, 2026 ·
Financing Dyadic is registering for resale up to 3,625,000 shares of common stock issuable on exercise of warrants at $0.84 per share. The company will receive no proceeds from the selling stockholders' sales. The stock closed at $0.42 on September 17, 2026. Form 424B3 · SEC filing
Sep 11, 2026 ·
Financing Dyadic International is registering up to 3,625,000 shares of common stock for resale by selling stockholders, issuable on exercise of warrants at $0.84 per share. The company will not receive proceeds from the resale. Last reported Nasdaq price on September 10, 2026 was $0.49. Form S-1 · SEC filing
Aug 14, 2026 ·
Financing Dyadic agreed to sell 3,625,000 shares at $0.795 per share in a registered direct offering, plus concurrent private placement of warrants for 3,625,000 shares at $0.005 each with an $0.84 exercise price. Aggregate gross proceeds are expected to be about $2.9 million, closing on or about August 14, 2026. Form 8-K · SEC filing · Press release
Aug 13, 2026 ·
Financing Dyadic International is offering 3,625,000 common shares in a registered direct offering at $0.795 per share, for gross proceeds of $2,881,875.00, with Aegis Capital Corp. as placement agent. Concurrently, investors will buy warrants for 3,625,000 shares at an exercise price of $0.84. Form 424B5 · SEC filing
Aug 12, 2026 ·
Earnings Q2 2026 revenue was $961,138, flat versus last year, while cost of revenue rose 60.4% to $984,165. Net loss widened to $2,123,884, or $(0.06) per share, and cash fell to $4,794,798 from $8,587,289 at year-end 2025. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
DYAI holds $4.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $1.7M/quarter from operations,
an estimated runway of 8.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:67 · High
Cash runway 8 months +30
ATM program on file since Mar 2026 +15
Going-concern doubt in the latest 10-Q +15These factors include, but are not limited to (i) our history of net losses, and management’s related conclusion that there is substantial doubt about our ability to continue as a going concern for 12 months following November 13, 2026, the date the financial statements are issued; (ii) market and regulatory…10-Q, Nov 2026
Share count 40,091,203 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full DYAI picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for DYAI and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.